Slide Show: Kidney Cancer

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Findings from DESTINY-Breast12 support the use of T-DXd for patients with HER2-positive metastatic breast cancer.

Jessica Cheng, MD

September 9th 2024

Addition of Capivasertib to Paclitaxel Fails to Improve OS in Metastatic TNBC

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.

Kristie L. Kahl

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Rahul Banerjee, MD, FACP;Noopur Raje, MD

September 2nd 2024

Consolidation Durvalumab Consistently Improves PFS/OS in LS-SCLC Subgroups

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

The magnitude of benefit with durvalumab was particularly consistent within prophylactic cranial irradiation and radiation subgroups in the ADRIATIC trial.

Russ Conroy

Adjuvant Durvalumab Does Not Improve DFS Across NSCLC PD-L1 Subgroups

The magnitude of benefit with durvalumab was particularly consistent within prophylactic cranial irradiation and radiation subgroups in the ADRIATIC trial.

Patients with NSCLC across various subgroups did not see a disease-free survival benefit with adjuvant durvalumab compared with placebo.

Ariana Pelosci

T-DXd Yields Enduring Intracranial Activity in HER2+ Breast Cancer

Patients with NSCLC across various subgroups did not see a disease-free survival benefit with adjuvant durvalumab compared with placebo.

Related Content

Kristi Rosa

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Findings from DESTINY-Breast12 support the use of T-DXd for patients with HER2-positive metastatic breast cancer.

Jessica Cheng, MD

September 9th 2024

Addition of Capivasertib to Paclitaxel Fails to Improve OS in Metastatic TNBC

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Kristie L. Kahl

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.

Rahul Banerjee, MD, FACP;Noopur Raje, MD

September 2nd 2024

Consolidation Durvalumab Consistently Improves PFS/OS in LS-SCLC Subgroups

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Russ Conroy

Adjuvant Durvalumab Does Not Improve DFS Across NSCLC PD-L1 Subgroups

The magnitude of benefit with durvalumab was particularly consistent within prophylactic cranial irradiation and radiation subgroups in the ADRIATIC trial.

Ariana Pelosci